Lymphoma
Showing 1 - 25 of 9,106
Lymphoma, Non-Hodgkin Lymphoma, B-Cell Trial (BAFF CAR-T)
Not yet recruiting
- Lymphoma, Non-Hodgkin Lymphoma, B-Cell
- BAFF CAR-T
- (no location specified)
Aug 16, 2022
DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma
- Loncastuximab Tesirine
- (no location specified)
Dec 13, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Mar 16, 2022
Living Conditions After Non-Hodgkin's Lymphoma in France
Not yet recruiting
- Non-hodgkin's Lymphoma
- Data collection
- Questionnaires
-
Dijon, FranceChu Dijon Bourgogne
Oct 13, 2022
Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Buparlisib, Ibrutinib)
Active, not recruiting
- Lymphoma
- +3 more
-
Basking Ridge, New Jersey
- +5 more
Jun 13, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 20, 2022
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,
Not yet recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- +6 more
- Bridging radiation therapy
- +2 more
- (no location specified)
Jan 4, 2023
PET/CT Vs Bone Marrow Biopsy in Exclusion of Bone Marrow
Not yet recruiting
- Lymphoma
- positron emission tomography for exclusion of bone marrow infiltration in lymphoma
- (no location specified)
Oct 28, 2022
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma Trial in Pittsburgh (Chimeric Antigen Receptor
Recruiting
- B-Cell Lymphoma
- +8 more
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
-
Pittsburgh, PennsylvaniaAHN Cancer Institute - West Penn Hospital
Aug 10, 2022
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell
Recruiting
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- +13 more
- Brentuximab Vedotin
- Pembrolizumab
-
Chicago, IllinoisNorthwestern University
Jun 15, 2022
Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell Trial in New York (Pharmacokinetics)
Recruiting
- Lymphoma
- +4 more
- Pharmacokinetics
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Sep 12, 2022
Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Tumors Trial in Frankfurt (Adriamycin, Cyclophosphamide, Cytarabine)
Completed
- Burkitt's Lymphoma
- +4 more
- Adriamycin
- +10 more
-
Frankfurt, GermanyUniversity Hospital, Medical Dept. II
Aug 17, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation
Active, not recruiting
- Grade 1 Follicular Lymphoma
- +6 more
- Ibrutinib
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jun 13, 2022
Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma Trial in Hangzhou (RD14-01 cell infusion)
Recruiting
- Mantle Cell Lymphoma
- +2 more
- RD14-01 cell infusion
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jul 6, 2022
A Study of People With CD30 Positive Lymphoma in China
Not yet recruiting
- Lymphoma
- (no location specified)
Aug 17, 2022
Cardiovascular Events Among Adults Relapsed or Refractory
Recruiting
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
- +9 more
- Electronic Health Record Review
-
Houston, TexasM D Anderson Cancer Center
May 24, 2022
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +4 more
-
Duarte, California
- +3 more
Jul 21, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)
Recruiting
- Lymphoma
- +3 more
- Venetoclax
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)
Not yet recruiting
- NK/T Cell Lymphoma
- +2 more
-
Guangzhou, Guangdong, China
- +1 more
Jan 12, 2023
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Lymphoma, Survivorship Trial in Boston (Interview with Clinicians, Field Test of UPLYFT with Lymphoma Survivors, Pilot of UPLYFT
Recruiting
- Lymphoma
- Survivorship
- Interview with Clinicians
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 14, 2022
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)
Not yet recruiting
- Lymphoma, Mantle-Cell
- +7 more
- Zilovertamab
- +2 more
- (no location specified)
Jun 21, 2022
T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- CD7 CAR-T cells
-
Shenzhen, Guangdong, ChinaLi Yu
Nov 11, 2022